Small Mobile Stem Cells Isolation for Autologous Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and utilizing stem cells for regenerative medicine face challenges such as difficulty in obtaining sufficient cells for autologous transfer, sensitivity to incubation conditions, and inefficiencies in inducing cells to form complex tissue structures in vitro, leading to limitations in treating tissue and organ damage effectively.
Innovation Solution
The isolation and culture of Small Mobile Stem cells (SMS) from various sources, including umbilical cord blood and solid tissues, which exhibit robust growth, resistance to adverse conditions, and the ability to form complex tissue-like structures in vitro without serum, enabling efficient autologous cell therapy and tissue replacement.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional stem cell isolation methods are used, then stem cells can be obtained from various sources, but insufficient cells are obtained for autologous transfer
Solution Approach 1:
The patent changes the isolation parameter from traditional bone marrow focus to peripheral blood and umbilical cord blood, and modifies the cell selection criteria to include CD34+ and CD133+ markers with specific size characteristics (3-10 μm), enabling sufficient cell yield for autologous transfer
Solution Approach 2:
The patent creates a cell line that replicates the functional characteristics of embryonic stem cells (pluripotency, self-renewal) while using adult-derived cells, achieving the desired cell quantity without the ethical and practical limitations of hES cells
2Duration of action of moving object
If stem cells are cultured in conventional conditions, then cell growth occurs, but cells are sensitive to incubation conditions
Solution Approach 1:
The patent modifies culture conditions by using defined media without serum, controlling pH at 7.2-7.4, maintaining temperature at 37°C, and using specific growth factors (bFGF, EGF, TGFβ) to achieve robust, stable cell growth over extended periods
Solution Approach 2:
The SMS cells exhibit self-renewal capability and can maintain their proliferative state without external intervention, forming stable colonies and maintaining genomic stability across multiple passages without requiring complex conditioning
3Productivity
If conventional methods are used to induce tissue structure formation, then some differentiation occurs, but complex tissue structures are not formed efficiently
Solution Approach 1:
The patent performs preliminary differentiation induction by treating SMS cells with specific growth factors (bFGF, EGF, TGFβ) and cytokines before transplantation, enabling cells to pre-form complex tissue structures in vitro that resemble native tissue architecture
Solution Approach 2:
The SMS cells demonstrate multi-lineage differentiation potential, capable of forming various tissue types (neural, muscular, skeletal, cartilaginous) from a single cell population, eliminating the need for multiple specialized cell lines
Data Source
AI summary
The presently disclosed subject matter relates, in general, to the identification, isolation, and use of a population of stem cells isolated from umbilical cord blood, peripheral blood, and/or other sources that are referred to herein as Small Mobile Stem cells (short: SMS). More particularly, the presently disclosed subject matter relates to isolating said SMS stem cells and employing the same, optionally after in vitro manipulation, to treat tissue and/or organ damage in a subject in need thereof.